

### **Progress Report Instructions**

- 1) All sections must be completed
- 2) **One electronic** copy should be **e-mailed** to the CSSP and another **hard copy** to be signed and **sent by regular mail** (accompanied by copies of any equipment or travel expenses invoices) to the BA/CSSP by the date specified in the original funding Memorandum of Understanding.

**Center for Special Studies and Programs**

**Bibliotheca Alexandrina**

**El Shatby, Alexandria, Egypt 21526**

**Fax: + (203) 4820469**

**E-mail: [cssp@bibalex.org](mailto:cssp@bibalex.org)**

# Investigating CSMD1 signalling pathways and evaluating their prognostic values in breast cancer patients

## Progress Report No. 1/3

Researcher Name: Mohamed Kamal Saleh

### Description of the Current Phase

**phase No. 1 of the project includes the following activities:**

- 1- Receiving RNA samples from our European counterpart, making up cDNA and testing its quality.
- 2- Selecting genes to be included in the qPCR arrays to be ordered after receiving the 2<sup>nd</sup> installment of the grant.
- 3- Optimizing Immunohistochemistry staining (preparation of positive controls).

### 2. Phase Key results and activities

Key results of Phase No. <1/3>	Accomplishment Status of each activity < done, pending>	Causes of delay (if any)	Impact
<b>Result 1</b> <b>Activity 1:</b> RNA samples have been arrived from England. <b>Activity 2:</b> cDNA has been made up from the RNA using cDNA synthesis kit. <b>Activity 3:</b> The integrity of the RNA was tested using GAPDH house keeping gene using PCR.	<i>All activities have been successfully accomplished and the RNA integrity was fine (please find attached a PCR</i>	No delay	<i>No changes in the project plan</i>

	<i>picture for the tested sample.</i>		
<p><b>Result 2</b> <b>Activity 1:</b> Designing the CSMD1 qPCR array.</p>	<p><i>Done by using GeneSeive software to include the most functionally relevant genes to CSMD1. Please find attached a list of the selected genes.</i></p> <p><i>Lonza company has been contacted to manufacture the array. Waiting to receive the 2<sup>nd</sup> instalment to be able to place the order.</i></p>	<i>No delay</i>	<i>No changes to the project plan</i>
<p><b>Result 3: Optimizing Immunohistochemistry (IHC) staining</b></p> <p><b>Activity 1:</b> Preparation of a formalin fixed paraffin embedded block for a mouse brain to be used as positive controls for all the subsequent IHC staining.</p>	<i>Done</i>		

### 3. Enumeration of key results expected over the next reporting period

Key Results	Comment <Mention changes, if any, according to your original proposal>
Result 1: Ordering and receiving the customized CSMD1 qPCR array (it takes 6 weeks to arrive)	No changes
Result 2: Running the qPCR arrays for CSMD1 positive and negative cells and detecting changes in gene expression in response to CSMD1.	No changes
Result 3: Optimizing specific qPCR assays for genes which showing alterations in their expression	No changes
Results 4: Continuing optimization of the IHC staining and get CSMD1 stained on the positive control.	No changes

### 4. Constraints:

Limitations generally outside the control of the project, which may negatively affect the project scope.

Constraints	Changes planned to overcome
<Briefly describe each one>	

### 5. Budget:

Please complete the expenditure statement. Identify the expenditure type (travel, materials, overhead, equipments, books...etc.), source of funding (BA/CSSP, other source, in-kind contribution), and cost per item. *Additional rows may be added if necessary.*

Total Budget in EGP*: Amount dispersed in the current phase in EGP:					
Expenditure types	Items	Number of Units	Cost per Unit in EGP	Total in EGP	
				BA Fund	Others < Please mention it>
Equipment					
Travel					
Research expenses	cDNA Synthesis kit	1	3000	3000	
	Sybgreen Master mix	1	3000	3000	
	Primers	10	2000	2000	

\* EGP: Egyptian Pound (1\$ = 5.9 EGP)

<b>Others</b> <i>(please mention it)</i>					
<b>TOTAL</b>					

**By signing this document, the grantee agrees to the following:**

**I declare that the information provided in this report is true, complete, and accurate and give consent to the BA/CSSP grant to verify any information provided in this report.**

**Name: Mohamed Kamal Saleh**

**Signature: Mohamed Kamal**

**Date: 28.07.12**